Intelligent Production Systems for Cell Therapy
Intelligent Production Systems for Cell Therapy
Intelligent Production Systems for Cell Therapy
OUR GENESIS
OUR GENESIS
Celleo originated at the intersection of great biology and great engineering. Sparks fly at the intersection.
Our mission is to enable Cell & Gene Therapies to deliver population-level health outcomes, realizing the extraordinary potential of humanity’s most powerful therapeutic modality – our cells, augmented.
We contribute intelligent production systems for the manufacture of Cell & Gene Therapies.
Our 3 co-founders each bring nearly 20 years of deep industry experience in the development and production of Cell & Gene Therapies. Celleo develops GMP production systems in collaboration with leading commercial biotherapeutics players, developers of novel therapeutics at pre-clinical to clinical stage, CDMOs, and major university medical centers.
Our production systems seek to accommodate, not dictate, the diversity of processes, modalities and business models characteristic of our vibrant industry.
Steve Jobs predicted “…the biggest innovations of the 21st century will be at the intersection of biology and technology.” Today’s Cell & Gene Therapy industry is approaching a tipping point – from a limited set of therapeutics changing the lives of a fortunate few, to a broadly available toolkit for physicians providing a new standard of personalized care. We’re here to hasten that transition.
Millions of patients in need deserve it.
Thousands of Cell Therapy professionals deserve it too.
MEET THE FOUNDERS
MEET THE FOUNDERS
NEWS
NEWS
First Larkem® V40 customer delivery
Celleo’s first production Larkem® V40, with some of the development team. Celleo is proud to announce the first customer delivery of a production Larkem® V40. The system has been installed at the US facilities of a biopharma multinational, who manufacture groundbreaking CAR-T therapies for patients worldwide. “It’s a privilege to support expanded manufacture of the world’s most important cell therapies,” announced CEO David Kneen. “Today’s milestone reflects an extraordinary team effort, highlighting the experience and dedication of Celleo’s team, as well as the incredible contribution of our collaborators worldwide.” Celleo’s Larkem® V40 is a closed, automated vial filling system for cell therapy production. The system completes automated vial fills in minutes in a Grade C/D environment, delivering precise, homogeneous samples whilst being gentle on biology. Applications include GMP manufacture of cell product and QC samples, cell banks, intermediates, viral vector and critical reagents. Larkem drives robust, scalable cell therapy production by eliminating reliance on high-grade cleanrooms and replacing a cumbersome manual workflow with simple, intuitive automation. “Extensive internal studies, backed by independent research at world-renowned institutes, have built strong confidence in the system’s capability across diverse cell and gene therapy applications,” noted Celleo Head of Biology Dr Nicholas Boyd. “The research consistently demonstrates biological integrity across all key metrics, whilst delivering the operational and scalability benefits of rapid, closed processing.” This milestone is an important step in Celleo’s mission – to drive [...]
